Disialosyl globopentaosylceramide (DSGb5) as a biomarker of prostate cancer
Ito, A.; Kawasaki, Y.; Kakoi, N.; Shimada, S.; Saito, S.; Arai, Y.
Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 196-200
2016
ISSN/ISBN: 0047-1852 PMID: 27344728 Document Number: 686907
Document emailed within 1 workday
Related Documents
De la Taille, A.; Cao, Y.; Sawczuk, I.S.; Nozemu, T.; d'Agati, V.; McKiernan, J.M.; Bagiella, E.; Buttyan, R.; Burchardt, M.; Olsson, C.A.; Bander, N.; Katz, A.E. 2000: Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion Cancer Detection and Prevention 24(6): 579-588Chavan, S.V.; Chavan, N.R.; Balaji, A.; Trivedi, V.D.; Chavan, P.R. 2011: A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml Indian Journal of Medical Research 134: 458-462
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Snead, M.C.; Melendez, J.H.; Kourtis, A.P.; Chaney, D.M.; Brown, T.M.; Black, C.M.; Mauck, C.K.; Schwartz, J.L.; Zenilman, J.M.; Jamieson, D.J.; Macaluso, M.; Doncel, G.F. 2014: Effect of lubricants and a vaginal spermicide gel on the detection of prostate specific antigen, a biomarker of semen exposure, using a quantitative (Abbott ARCHITECT) assay Contraception 89(2): 134-138
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Yucel, E.; Ilter, E.; Aksungar, F.B.; Celik, A.; Peker, B.H.; Serifsoy, E.; Bozkurt, S. 2017: HE4: really a novel biomarker for ovarian cancer? European Journal of Gynaecological Oncology 38(1): 59-64
Nagasaka, T.; Mori, Y.; Umeda, Y.; Fujiwara, T. 2012: Biomarker for colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 70(5): 802-808
Presl, J.; Kučera, R.; Topolčan, O.; Novotný, Z.; Vrzalová, J.; Fuchsova, R.; Betincová, L.; Rokyta, Z. 2012: HE4 a biomarker of ovarian cancer Ceska Gynekologie 77(5): 445-449
Miyazaki, J.; Nishiyama, H. 2012: Biomarker for bladder cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(1): 48-53
Kondo, T. 2012: Biomarker development by cancer proteomics Nihon Rinsho. Japanese Journal of Clinical Medicine 70(5): 754-758
Walsh, T.; Warner, L.; Macaluso, M.; Frezieres, R.; Snead, M.; Wraxall, B. 2012: Prostate-specific antigen as a biomarker of condom failure: comparison of three laboratory assays and self-reported condom use problems in a randomized trial of female condom performance Contraception 86(1): 55-61
Walsh, T.; Warner, L.; Macaluso, M.; Frezieres, R.; Snead, M.; Wraxall, B. 2012: Prostate-specific antigen as a biomarker of condom failure: comparison of three laboratory assays and self-reported condom use problems in a randomized trial of female condom performance Contraception 86(1): 55-61